Loading…
Manufactures specialty pharmaceutical intermediates, mainly for contrast media (imaging agents) and high-intensity sweeteners.
Manufactures specialty pharmaceutical intermediates, mainly for contrast media (imaging agents) and high-intensity sweeteners.
Supplies intermediates, the chemical building blocks, to a small group of global contrast-media makers under long relationships, so sales rest on a few buyers and on their production plans. Saccharin and custom-synthesis work add variety, and contrast-media volumes follow imaging procedures worldwide.
In one line: A niche pharma-intermediate/specialty-chemical maker.
Moat: narrow (process know-how, customer qualification). Specialized iodine chemistry and long-qualified supply relationships with global contrast media makers.
Headquarters: Mumbai, India · Founded: 1968 · Employees: 581
Size Blue Jet Healthcare (BLUEJET.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.11B, the 568th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹553.80 on 6 Nov 2026.
Performance Over six months the shares gained 12.9%, against -17.7% for the median peer and 0.0% for the India market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue fell 27.5% over the last twelve months (peer median +12.8%); the operating margin is 27.8% (peer median 7.7%).
Valuation It trades at 32.5× forward earnings against a peer median of 23.8× (2nd most expensive of 12).
Price implies For today's price to make sense, revenue must grow about 49% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +35 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.3 points below its cost of capital (18.8% WACC).
Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹8.86B | ₹9.42B | ₹10.2B | ₹7.08B | ₹7.18B |
| Revenue growth | — | -8% | +45% | -1% | — |
| Gross profit | ₹3.94B | ₹3.62B | ₹4.41B | ₹2.77B | ₹2.70B |
| EBITDA | ₹2.71B | ₹2.96B | ₹3.79B | ₹2.35B | ₹2.21B |
| Net income | ₹2.35B | ₹2.48B | ₹3.05B | ₹1.64B | ₹1.60B |
| Free cash flow | n/a | ₹1.19B | -₹289M | ₹674M | ₹823M |
| Capital expenditure | n/a | ₹2.19B | ₹799M | ₹1.74B | ₹593M |
| Total debt | n/a | ₹437M | ₹215M | ₹31.1M | ₹49.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Blue Jet Healthcare BLUEJET.NS | $1.11B | +13% | -28% | 28% | 32.5× | 49.0% |
| Neuland Laboratories NEULANDLAB.NS | $2.68B | +14% | +50% | 26% | 54.3× | n/a |
| Divi's Laboratories DIVISLAB.NS | $29.0B | +54% | +16% | 31% | 82.0× | 50.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BLUEJET.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.3% | -6.8% | 4th highest of 21 |
| 6-month return | +12.9% | -17.7% | 3rd highest of 21 |
| Distance from 52-week high | -19.6% | -41.5% | 3rd highest of 21 |
| Revenue growth (TTM) | -27.5% | +12.8% | 2nd lowest of 19 |
| Operating margin | 27.8% | 7.7% | 2nd highest of 19 |
| Forward P/E | 32.5× | 23.8× | 2nd most expensive of 12 |
| Growth the price implies (Req g, 7 yrs) | 49.0% | 5.3% | most demanding of 11 |
| Growth delivered (Del g) | +13.8% | +7.1% | 4th highest of 11 |
| Hurdle (Req g minus delivered) | +35.2 pp | -0.3 pp | 2nd most demanding of 11 |
| ROIC minus cost of capital | -5.3 pp | +0.1 pp | 6th lowest of 17 |
| EV / EBITDA | 38.6× | 14.6× | most expensive of 5 |
| Net debt / EBITDA | -1.2× | -0.5× | 3rd least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Blue Jet Healthcare BLUEJET.NS | India | $1.11B | +13% | -28% | 28% | 32.5× | 49.0% | +13.8% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.11B | -13% | -7% | 3% | n/a | 3.3% | +6.5% |
| Bio-Thera Solutions 688177.SS | China | $1.10B | -14% | +24% | -44% | n/a | n/a | n/a |
| ST Pharm 237690.KS | South Korea | $1.12B | -52% | +26% | 18% | 27.9× | n/a | n/a |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $1.10B | -51% | +19% | 9% | 49.2× | 13.9% | +4.9% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.10B | -29% | +103% | 24% | 10.6× | 8.6% | -4.5% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $1.09B | -15% | -4% | 2% | 26.5× | n/a | n/a |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.13B | -18% | +17% | 20% | 12.8× | 1.1% | +22.8% |
| Aurisco Pharmaceutical 605116.SS | China | $1.13B | -18% | +9% | 28% | 15.4× | 1.5% | +18.7% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.13B | -34% | +32% | 14% | n/a | n/a | n/a |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.09B | -35% | -2% | 13% | 26.5× | 5.5% | +7.7% |
| BeBetter Med 688759.SS | China | $1.08B | -49% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.08B | -2% | +27% | 4% | 22.7× | 5.0% | +3.5% |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $1.07B | -15% | +8% | 7% | n/a | 34.1% | -6.0% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.07B | -38% | +117% | -89% | n/a | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.15B | -1% | -23% | -131% | n/a | n/a | n/a |
| Viyash Scientific VIYASH.NS | India | $1.07B | +3% | +96% | 13% | 30.3× | 38.6% | +20.4% |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.07B | +27% | +5% | 24% | 12.4× | -5.7% | +12.7% |
| Seaport Therapeutics SPTX | United States | $1.15B | +34% | n/a | n/a | n/a | n/a | n/a |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $1.07B | -47% | -55% | -457% | n/a | n/a | n/a |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $1.06B | -18% | -27% | -19% | 23.8× | n/a | n/a |